Table 1 Summary of clinical studies of mesenchymal stem cells therapy for acute-on-chronic liver failure
Included studies | Country | Design | Age(year) | Patients | Cell type | Total dose/kg body weight (average 50kg/person) | Administration route | Follow up | Main outcome measures | Cause of ACLF |
|---|---|---|---|---|---|---|---|---|---|---|
Shi et al (2012) | China | RCT | EG: 24 ± 8.75 CG: 45 ± 9 | EG: 24 CG: 19 | UC-MSCs | 0.5×107cells/kg | vein of the arm | 1,2,4,8,12,24,36, 48weeks | ALT,TBIL,ALB,CHE,PTA,MELD score | HBV |
Xu et al (2019) | China | RCT | EG: 40.67 ± 9.89 CG: 44.97 ± 11.83 | EG: 30 CG: 30 | UC-MSCs | 1×106cells/kg | intravenous | 30,60,90,180weeks | ALT,TBIL,ALB,MELD score | HBV |
Li et al (2016) | China | RCT | EG: 40.67 ± 9.89 CG: 44.97 ± 11.83 | EG: 11 CG: 34 | UC-MSCs | 1×108cells/kg | intravenous | 4–24 months | HCC incidence, ALT,TBIL,ALB,MELD score | HBV |
Lin et al (2013) | China | RCT | EG: 40.04 ± 9.94 CG: 42.78 ± 8.4 | EG: 56 CG: 54 | UC-MSCs | 1.0–10×108cells/kg | intravenous | 1, 2, 3, 4, 8, 12 and 24 weeks | ALT,TBIL,ALB,MELD score | HBV |
Peng et al (2011) | China | RCT | EG: 42.19 ± 9.94 CG: 42.78 ± 8.4 | EG: 53 CG: 105 | BM-MSCs | UK | hepatic artery | 1,2,3,4,12, 24,36,48 weeks | ALT,ALB,TBIL,PT,MELD score | HBV |
Schacher et al (2021) | Brazil | RCT | EG: 55.8 ± 12.8 CG: 53.4 ± 14.4 | EG: 4 CG: 5 | BM-MSCs | 1×106cells/kg | intravenous | UK | ALT,TBIL,ALB,PT,CRP | HBV |
Jia et al (2020) | China | non-RCT | 16–60 | 513 | UC-MSCs | 1×106cells/kg | intravenous | 1, 4, 12, 24 | ALT,TBIL,AST | HBV |